Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic avenue for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 agents demonstrate promising therapeutic outcomes in treating type